On a DART annual-report basis, revenue rose from KRW 274 billion in 2022 to KRW 292.1 billion in 2023 (up 6.6% year on year), KRW 308.3 billion in 2024 (up 5.6%) and KRW 309.1 billion in 2025 (up 0.3%).
Revenue has increased for three consecutive years from 2023 through 2025, and 2025 is the largest year in the 2022 to 2025 span. Operating profit was KRW 23.2 billion in 2022, KRW 20.5 billion in 2023 (down 11.6%), KRW 31.6 billion in 2024 (up 54.4%) and KRW 26.8 billion in 2025 (down 15.3%).
Operating margin was 8.5%, 7.0%, 10.3% and 8.7% in the same years. The company attributed the 2024 operating profit increase to steady growth across all business divisions.
Profit attributable to controlling shareholders reached KRW 39.2 billion in 2024 (up 107.5%), a figure that included a KRW 24.3 billion corporate tax refund and therefore a base effect. It then fell 38.4% to KRW 24.2 billion in 2025, which the company explained as a base effect.
Cost pressure from a higher share of merchandise sales and rising raw material costs were cited for the 2025 profit decline. Operating cash flow was KRW 17.3 billion in 2022, KRW 8.33 billion in 2023, KRW 38.2 billion in 2024 and KRW 24.1 billion in 2025.
The debt ratio rose from 47.4% in 2022 to 62.0% in 2025, and equity of KRW 290.4 billion at the end of 2025 was entirely attributable to controlling shareholders.
Quarterly operating profit fell from KRW 9.78 billion in the third quarter of 2025 to KRW 4.22 billion in the fourth quarter (down 56.8% from the prior quarter), then to KRW 3.59 billion in the first quarter of 2026, before recovering to KRW 7.15 billion in the second quarter and KRW 11.9 billion in the third quarter.
The first-quarter 2026 profit decline reflected a base effect from one-off tax refund gains in the first quarter of 2025, on top of weaker demand for respiratory treatments. Profit attributable to controlling shareholders over the last four quarters totals KRW 24.6 billion.